Valion Bio, Inc. (VBIO) Form 8-K — Oct 27, 2026
$VBIOForm 8-KItems 1.01, 3.02, 9.01Filed Oct 27, 2026, 6:01 AM ET0001437749-26-033552Original filing
Valion Bio closed incremental tranches of its Series B and Series C preferred financings on October 26, 2026, issuing 50 Series B preferred shares for $50,000 and 4,717.73 Series C preferred shares for $4,717,717.61 to 3i, LP and other purchasers. Of the Series C proceeds, $3,217,717.61 was retained by the purchasers to satisfy overdue cash true-up payments, with only $1.5 million arriving as new cash — underscoring the company's cash constraints under these structured financing terms.
Key figures
- New cash received
- 1500000
- Warrant exercise price
- 1.0092
- Series b closing shares
- 50
- Series b total capacity
- 8400000
- Series b warrant shares
- 1539
- Series c total capacity
- 75000000
- Series c warrant shares
- 2524343
- Series c purchased to date
- 6000000
- Series c remaining capacity
- 31500000
- Series c 3i purchased to date
- 13637000
- Series c 3i remaining capacity
- 23863000
- Series b closing purchase price
- 50000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.